Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVY: Enavogliflozin for Coronary Microvascular Function in Obese T2D
NCT06782139Phase 4Recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Enavogliflozin with Placebo (2 arms). Primary endpoint: Coronary microvascular function at 12 weeks. Started Jan 2025; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06782139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782139.